Taken together, these data indicate that OVesRAGE virus inhibits oHSV therapy-induced HMGB1-RAGE signaling in the TME, thereby allowing increased virus spread and enhancing anti-tumor efficacy in vivo. Here, HMGB1 is linked to neoplasm.